MedTrace Logo

Pembrolizumab and Olaparib in Cervical Cancer Patients

NCT04483544 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-04-29

Study results available
· View outcomes & findings →

Summary

The study is a non-randomized, open-label phase II clinical trial to test the investigational combination of the drug pembrolizumab with the drug olaparib in patients diagnosed with advanced or recurrent cervical carcinoma after standard chemotherapy.

Conditions

Interventions

DRUG

pembrolizumab

PD-1 inhibitor pembrolizumab, 200mg intravenously (IV) every 3 weeks

DRUG

olaparib

PARP inhibitor olaparib 300 mg orally, twice daily (BID)

Sponsors & Collaborators

  • Florida Department of Health

    collaborator OTHER_GOV

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Baptist Health South Florida

    lead OTHER

Principal Investigators

  • John P. Diaz, MD · Miami Cancer Institute at Baptist Health Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-03
Primary Completion
2024-12-12
Completion
2024-12-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04483544 on ClinicalTrials.gov